35 Crosby Drive
Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic and medical imaging systems dedicated to serving the healthcare needs of women, and a leading developer of innovative imaging technology for digital radiography and breast imaging applications. Hologic's core business units are focused on mammography and breast biopsy, osteoporosis assessment and mini C-arm and extremity MRI imaging for orthopedic applications.
563 articles with Hologic
Hologic to Introduce Its Second High-Throughput Molecular Assay for the Novel Coronavirus (SARS-CoV-2)
Hologic, Inc. (Nasdaq: HOLX) announced today that it plans to launch a new Aptima® molecular assay to detect the SARS-CoV-2 virus that will run on its market-leading Panther® system.
Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal second quarter ended March 28, 2020.
Hologic Announces Preliminary Revenue Results for Second Quarter of Fiscal 2020, Withdraws 2020 Financial Guidance due to COVID-19 Pandemic
Hologic, Inc. announced preliminary revenue results for its second fiscal quarter ended March 28, 2020, and withdrew its 2020 financial guidance due to the uncertain economic impact of the COVID-19 pandemic.
Hologic to Announce Financial Results for the Second Quarter of Fiscal 2020 on Wednesday, April 29, 2020
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the second quarter of fiscal 2020 on Wednesday, April 29, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time. Interested participants may listen to the call by dialing 888-204-4368 (in the United States and Canada) or +1 323-994-2
Hologic’s Molecular Test for the Novel Coronavirus, SARS-CoV-2, Receives FDA Emergency Use Authorization
Only High-Throughput System to Enable Simultaneous Testing for SARS-CoV-2 and Other Common Respiratory Viruses, Boosting Efficiency and Increasing Clinical Insight
Hologic (Nasdaq: HOLX) announced today the 1,000th placement of a Panther system, the Company’s market-leading automated molecular instrument, in a United States diagnostics laboratory
Hologic, Inc. announced that the Company will present at these upcoming investor conferences
New products offer increased flexibility and efficiency for low- to high-volume molecular testing laboratories
Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal first quarter ended December 28, 2019.
Hologic’s First Sustainability Report Highlights Global Corporate Citizenship Efforts in Fiscal 2019
Hologic, Inc. announced the release of the Company’s first sustainability report, Making a Unique Difference in the World.
Hologic, Inc. announced preliminary revenue results for its first fiscal quarter ended December 28, 2019.
Hologic to Announce Financial Results for the First Quarter of Fiscal 2020 on Wednesday, January 29, 2020
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the first quarter of fiscal 2020 on Wednesday, January 29, after the market closes.
The webcasts will be available for 30 days following the event.
Hologic, Inc. (Nasdaq: HOLX) announced today that it has completed the previously announced divestiture of its Cynosure medical aesthetics business to an affiliate of investment funds managed by Clayton, Dubilier & Rice for a total purchase price of $205 million in cash, less certain closing adjustments
Women’s Healthcare Leader Hologic to Showcase Comprehensive Portfolio of Breast and Skeletal Health Solutions at RSNA 2019
Company reinforces breast health leadership with innovative new products, breakthrough Artificial Intelligence-powered platform and prestigious IMV ranking
Each presentation will be webcast live and may be accessed through a link on the investors section of Hologic’s website at http://investors.hologic.com.
Hologic, Inc. announced that it has entered into a definitive agreement to sell its Cynosure medical aesthetics business to an affiliate of investment funds managed by Clayton, Dubilier & Rice for a total purchase price of $205 million in cash, subject to certain closing adjustments.
Clayton, Dubilier & Rice today announced an agreement under which CD&R-managed funds will acquire Cynosure, LLC, a leader in medical aesthetics systems and technologies, from Hologic, Inc. (NASDAQ:HOLX).
Hologic, Inc. (Nasdaq: HOLX) announced today that the U.S. Food and Drug Administration (FDA) has approved 3DQuorum™ Imaging Technology, powered by Genius AI™. 3DQuorum technology works in tandem with Hologic’s Clarity HD™ high resolution imaging technology to reduce tomosynthesis image volume for radiologists by 66 percent
Hologic, Inc. announced the Company’s financial results for the fiscal fourth quarter ended September 28, 2019.